The final amendments on the drug pricing regulations were announced by the Government of Canada due to excessive prices of the patented drugs with the new regulatory tool. The demand to lower down the excessive prices by the Canadian Government is to make the patented drugs more affordable.
This action from the government seems to have received mixed reactions. With this new amendment coming in effect and other changes in price control, Health Canada has decided to bring in changes in the lists of the countries that it previously had to set its drug prices by drawing comparisons. U.S and Switzerland are the top two countries amongst other countries that have the highest patent drug prices and have been explicitly ramified from the list of comparison under the new regulations.